- ?? $2.1M raised in initial seed round, at $15M valuation cap
- ?? Team at the forefront of aging research for decades, collectively authoring 200+ papers
- ?? Our platform delivers drug candidates to slow aging at a success rate of 20%
- ?? Funds will be used to test 10-15 of our hits in aging mice
Gerostate Alpha is a new pharmaceutical company dedicated to treating aging and age-related disease. Incubating at the Buck Institute for Research on Aging, we develop breakthrough pharmaceuticals through proprietary innovations to mitigate and reduce the effects of aging.
Phase 2/3 with multiple hits covering different aspects of aging, we will be the leading company revolutionizing medicine